Considering the very limited benefit offered by therapies targeting K-Ras, it is important to identify novel molecular interactors that may help design novel clinical approaches to improve the prognosis and therapy of K-Ras-dependent lung cancers. The gene discussed is KRAS; the disease is lung cancer.